Palisade Bio (PALI) Interest & Investment Income (2010 - 2021)
Palisade Bio (PALI) reported Interest & Investment Income of $3917.0 for Q1 2021, down 70.52% year-over-year from $13289.0 in Q1 2020, and down 30.02% on a QoQ basis from $5597.0 in Q4 2020.
Palisade Bio (PALI) has 12 years of Interest & Investment Income data on file, last reported at $3917.0 in Q1 2021.
- Quarterly Interest & Investment Income fell 70.52% year-over-year to $3917.0 in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $24160.0 (down 53.56% YoY) and the FY2020 annual result came in at $33532.0, down 50.49% from the prior year.
- Interest & Investment Income slipped to $3917.0 in Q1 2021 per PALI's latest filing, from $5597.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $29000.0 in Q1 2019 and bottomed at $3917.0 in Q1 2021.
- The 5-year median for Interest & Investment Income is $15234.0 (2019), against an average of $14954.6.
- The widest annual swing landed in 2017, when Interest & Investment Income surged 87.53%; it then tumbled 70.52% in 2021.
- Tracing PALI's Interest & Investment Income over 5 years: stood at $17274.0 in 2017, then surged by 38.35% to $23898.0 in 2018, then slumped by 47.09% to $12645.0 in 2019, then sank by 55.74% to $5597.0 in 2020, then plunged by 30.02% to $3917.0 in 2021.
- Per Business Quant, the three latest PALI Interest & Investment Income figures stand at $3917.0 (Q1 2021), $5597.0 (Q4 2020), and $7731.0 (Q3 2020).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 3,917.00 |
| Dec 31, 2020 | 5,597.00 |
| Sep 30, 2020 | 7,731.00 |
| Jun 30, 2020 | 6,915.00 |
| Mar 31, 2020 | 13,289.00 |
| Dec 31, 2019 | 12,645.00 |
| Sep 30, 2019 | 15,234.00 |
| Jun 30, 2019 | 10,852.00 |
| Mar 31, 2019 | 29,000.00 |
| Dec 31, 2018 | 23,898.00 |
| Sep 30, 2018 | 17,619.00 |
| Jun 30, 2018 | 19,514.00 |
| Mar 31, 2018 | 17,749.00 |
| Dec 31, 2017 | 17,274.00 |
| Sep 30, 2017 | 18,099.00 |
| Jun 30, 2017 | 14,013.00 |
| Mar 31, 2017 | 20,883.00 |
| Dec 31, 2016 | 16,973.00 |
| Sep 30, 2016 | 17,293.00 |
| Jun 30, 2016 | 13,433.00 |
| Mar 31, 2016 | 11,136.00 |
| Dec 31, 2015 | 15,747.00 |
| Sep 30, 2015 | 24,149.00 |
| Jun 30, 2015 | 16,084.00 |
| Mar 31, 2015 | 13,569.00 |
| Dec 31, 2014 | 12,384.00 |
| Sep 30, 2014 | 13,127.00 |
| Jun 30, 2014 | 17,422.00 |
| Mar 31, 2014 | 24,718.00 |
| Dec 31, 2013 | 22,664.00 |
| Sep 30, 2013 | 18,776.00 |
| Jun 30, 2013 | 16,635.00 |
| Mar 31, 2013 | 9,925.00 |
| Dec 31, 2012 | 12,553.00 |
| Sep 30, 2012 | 5,411.00 |
| Jun 30, 2012 | 7,475.00 |
| Mar 31, 2012 | 8,715.00 |
| Dec 31, 2011 | 6,458.00 |
| Sep 30, 2011 | 11,463.00 |
| Jun 30, 2011 | 20,143.00 |
| Mar 31, 2011 | 22,892.00 |
| Dec 31, 2010 | 26,408.00 |
| Sep 30, 2010 | 17,406.00 |
| Jun 30, 2010 | 9,653.00 |